Credit Suisse Upgrades Novartis (NVS) to Neutral
More News related to NVS
- A Competing Bid for Crucell NV (CRXL)?
- BridgewaterEquity.com Free Fundamental Sector & Market Research on NVS, JNJ, GM and DOW
- Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: BMY, JNJ, PFE, NVS, GSK, ABT
- New Data Show Zometa(R) Enhances Impact of Chemotherapy on Reducing Breast Tumor Size
- Wachovia Upgrades Alcon (ACL) to Outperform, Strong Chance Company Acquired by Novartis (NVS)
More News related to Upgrades
- Sterne Agee Downgrades World Acceptance Corp. (WRLD) to Neutral
- B. Riley Downgrades Trustmark (TRMK) to Sell
- B. Riley Downgrades Big 5 Sporting Goods (BGFV) to Neutral
- Sterne Agee Downgrades Suntrust Bank (STI) to Neutral
- Lazard Downgrades Allergan (AGN) to Hold
Credit Suisse upgrades Novartis (NYSE: NVS) from Underperform to Neutral.
Novartis AG is a Switzerland-based company, which is engaged in the research, development, manufacture and marketing of medicines.
Related Categories
UpgradesStocks Mentioned
-1.46Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
